Company intelligence / Profile preview
IMD Pharma
Toulouse, Occitanie, Franceimd-pharma.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
IMD Pharma has developed a new class of drug candidates using phosphorus dendrimer technology to rebalance dysregulated immune systems in chronic inflammatory diseases. Their lead programs are currently at the pre-clinical stage, with promising potential to address unmet needs where current immunosuppressive therapies fail in up to 40% of cases. No clinical results have been published yet as all programs remain preclinical.
- Therapeutic areas
- DermatologyRheumatologyImmunologyNeurology
- Modalities
- Novel chemical modalities based on phosphorus dendrimer platforms
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on IMD Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMD Pharma.